CN1531978A - Method and device for filtering human plasma virus - Google Patents
Method and device for filtering human plasma virus Download PDFInfo
- Publication number
- CN1531978A CN1531978A CNA031159257A CN03115925A CN1531978A CN 1531978 A CN1531978 A CN 1531978A CN A031159257 A CNA031159257 A CN A031159257A CN 03115925 A CN03115925 A CN 03115925A CN 1531978 A CN1531978 A CN 1531978A
- Authority
- CN
- China
- Prior art keywords
- virus
- plasma
- lower cover
- loam cake
- filtering device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The present invention relates to method and apparatus for filtering human plasma virus. Combined membrane filtering and compatible filtering method is adopted. On one hand, the mechanical membrane filtering separates virus from plasma with membrane material of pore size smaller than the virus. On the other hand, membranes with affinity to various viruses are combined to eliminate various viruses from plasma.
Description
Technical field
The present invention a kind ofly carries out filtering method and device thereof to human plasma virus, relates to by human plasma being carried out extracorporeal filtration removing the method for viruses such as acquired immune deficiency syndrome (AIDS) in the blood plasma, hepatitis B.
Technical background
Acquired immune deficiency syndrome (AIDS) is caused by AIDS viral infection, causes the part of infected person's immunologic function or completely loses the minimizing of CD4+ lymphocyte number, then generator opportunistic infections, tumor etc., clinical manifestation is varied, and this disease spread speed is fast, case fatality rate is high, can't cure at present.
There is free infectious virus in the AIDSinfected patient blood, can be in initial infection plasma viral quantity up to 10
5-10
6Copies/ml.Because immune defense function effect can be reduced to 10 after several weeks
3-10
4Copies/ml.In the incubation period of after this several years and even more than ten years, it is constant that virus quantity maintains reduced levels substantially.Current research show incubation period inner virus be not low-level duplicating, duplicate dynamic balance state but be in high level, promptly virus produces every day in a large number, also be eliminated in a large number simultaneously, it is estimated that the half-life of HIV virus in blood plasma only is 6 hours, by the T lymphocyte half-life of its infection is about one and half, calculates thus in human body every day that the HIV virus that produces and remove is more than 1,000,000,000 (10.3 * 10
9/ d), in order to escape immune pursuing and attacking, virus constantly morphs, and HIV is the very strong virus of a kind of variability (3.4 * 10
-5/ bp replicative cycle), consider virus high level duplicate, mutant quantity is surprising, and is widely different between the different Strain, in addition same strain only the several months just can change in same the infected's body.
The most effective at present treating AIDS method is efficient antiretroviral therapy (HAART is commonly called as HAART).From reverse transcriptase inhibitors and protease inhibitor two big class medicines, select 3 to 4 kinds of medications simultaneously,, suppress HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) to interrupt the life cycle of virus.Only rely on the medicine can not treatment of AIDS, HAART also is by the virus load in the medicine reduction blood of the different mechanisms of action, make patient's immune system can have surplus energy to remove the impalpable band poison cell of medicine, perhaps wait for the natural death of band poison cell.The defective of Drug therapy is conspicuous:
Because patient's individual variation, the high mutation rate of HIV virus and the continuous drug resistance that increases HIV, will be at the different phase of different patient's PD, constantly adjust medication, when for example adopting efficient antiretroviral therapy, if after efficient antiretroviral therapy 4-8 week, or virus load reduces more than 10 times unlike former level in the blood plasma, or through efficient antiretroviral therapy after 6 months, virus load does not reach the level of " can not surveying " in the blood plasma, or virus load occurs rising again in the blood plasma after efficient antiretroviral therapy descends to some extent or reaches the level of " surveying to go out ", will adjust medication.
Be three fens poison of medicine, the dispelling toxicity, detoxicating function of human body own reduces behind the infective virus, and behind the long-term prescription, the toxic and side effects of medicine can influence quality of life, and perhaps immunologic function also had a negative influence.Go up liang after year as zidovudine AZT (a kind of efabirenz), scientist finds that it may destroy user's bone marrow, and cause side effect such as pulmonary complication, serious anemia, unfortunately, AZT and similar medicine remain the main force of treatment acquired immune deficiency syndrome (AIDS).
For fear of the drug resistance phenomenon takes place, and make medicine selection in the future unrestricted, reduce the injury of drug toxicity to human body, reduce the financial burden that expensive medicine causes patient, be in acute stage or infect within 12 months and the acquired immune deficiency syndrome (AIDS) patient of asymptomatic stage does not adopt Drug therapy (following table), and as previously mentioned, in these stages, the virus in the blood may be among the high-level husband.
The acquired immune deficiency syndrome (AIDS) antiviral therapy scheme of China
| The clinical phase | CD4 counting, virus load, other | Antiviral therapy |
| Acute stage or infect within 12 months | Any level | Should not treat |
| Asymptomatic stage | CD4＞500/mm 3RNA＜30000 copy/ml blood plasma | Should not carry out |
| Asymptomatic stage | CD4＜350/mm3 RNA＞30000 copy/ml blood plasma | Carry out |
| Symptom phase in non-whole latter stage is after secondary infection is controlled | Any level | Can carry out |
| The symptom phase | Whole latter stage | Should not carry out |
| Period of pregnancy | Except that antenatal medication for the mother and baby blocks | Should not carry out |
In addition, hepatitis also is one of China's disease occurred frequently, and one of clinical manifestation of hepatitis patient is exactly that glutamate pyruvate transaminase (ALT) index raises, and this is the main project of diagnosis hepatocyte material injury, and its height often parallels with state of an illness weight.In acute hepatitis and chronic hepatitis and liver cirrhosis activity, ALT all can raise.Also with jaundice occurring, i.e. total bilirubin (TB) and the directly red matter of gallbladder (Bc): TB and Bc all can raise in various degree when some patient had a liver complaint.Hepatitis B is to propagate by the hepatitis B virus that is carried in the blood for another example, and China more country that is hepatitis B virus carriers, control gives to pay close attention to greatly and support to hepatitis B virus in the Chinese government.This shows, prevent and treat hepatitis the such populous nation of China still all is significant from the angle of social effect from the angle of life and health.
Summary of the invention
The objective of the invention is to propose a kind of virus load that can reduce in the blood, can not cause malicious secondary hurt simultaneously, can not be subjected to variation and the sex external plasmapheresis method of drug resistance and the device thereof of virus simultaneously human body.
The objective of the invention is to realize by the following method: adopt mechanical means, from patient's blood plasma, isolate virus.This method can not cause malicious secondary hurt to human body, can not be subjected to the variation and the drug resistance influence of virus simultaneously, can be used for any patient, can be used for any stage of the course of disease, can use separately, can be used with the other medicines treatment means yet.The present invention as acquired immune deficiency syndrome (AIDS), hepatitis B, hepatitis C etc., and can reduce glutamate pyruvate transaminase, total bilirubin (TB) and the direct red matter of gallbladder (Bc) applicable to multiple virus.
The solution of the present invention comprises two parts, i.e. cell separation part and viral separating part.
At first cell to be separated from blood plasma, can be adopted filtering method, just can make cell and separating plasma as the various membrane materials that adopt aperture 200-500 nanometer; Also can adopt the means of centrifugalize that cell is separated from blood plasma.The inventor recommends to adopt the means of centrifugalize.
Secondly, viral separation method be membrane filtration and or the compatible filtering method.So-called membrane filtration is meant with the aperture to be separated virus less than the various membrane materials of virus from blood plasma.And so-called compatible filtering is meant that with various virus is had the membrane filtration of affinity, by affine adsorption, with virus absorption to reach the purpose of removing.These films of different nature can be to use separately, the use that also can be grouped together, the use that also can combine of the film of same nature.The film less as the film that the aperture is bigger and aperture is used, and the film and the positively charged membrane that will contain silicon dioxide are used.
As, from morphology, HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) (HIV) granule is spherical in shape, diameter 90nm～130nm.Might adopt filter method to separate fully.Therefore for HIV virus, be the above films of 90 nanometers as long as adopt the aperture, the chemical composition of film must be a biologically inert, and human body is not had toxic and side effects, as cellulose, Kynoar, polysulfones etc., has a lot of commercial products available.For another example for the virus of hepatitis B virus fatty involucrums such as (HBV), the film that contains silicon dioxide that can adopt USP 4596660 to be proposed, it also has hepatitis C virus, hepatitis D virus, HIV (human immunodeficiency virus), HTLV-1, cytomegalovirus, Epstein-Barr virus etc. to common fatty envelope virus, and filter effect is very effective.
Accompanying drawing
Fig. 1 is a schematic perspective view of the present invention
Fig. 2 is a vertical view of the present invention
Fig. 3 is a front view of the present invention
Fig. 4 is a partial sectional view of the present invention
Embodiment
With reference to the accompanying drawings, in conjunction with the embodiments, the present invention is further described:
Defecator of the present invention comprises housing and combination filter membrane 4, and housing comprises loam cake 1 and lower cover 2, loam cake 1 is a disc, in being provided with plasma inlet 11 near center position, be provided with air vent 12 near the plasma inlet place, the periphery joint of loam cake 1 forms a circumferential projection 13.The lower surface of loam cake 1 is to having many spaced ribs 14, and these ribs 14 are that the center with loam cake is the center of circle, the evenly distributed circular arc of outwards dispersing.
During assembling, inner ring 3 places lower cover 2, and the bottom of inner ring 3 is placed on outermost circular arc rib 24 between lower cover 2 sidewalls, and accommodate in the annular breach 26 outside 33.Combination filter membrane 4 is accommodated and is fixed in the receiving space 22 of lower cover 2.Loam cake 1 fastens to that the blended rubber glue lumps together on the lower cover 2, and the circumferential projection 13 of loam cake 1 is accommodated in the circumferential groove 23 of lower cover 2, to increase gummed power.
After separating plasma was handled, the blood plasma with certain pressure entered the top layer of defecator combined films core 4 by the plasma inlet 11 at top, and 12 of air vents can guarantee the smooth inflow of blood plasma.Because blood plasma has certain pressure, it flows into the back just directly by combined films core 4 downward seepages via porch 11.Since the virus in the blood plasma can with can produce affinity with these filter membranes, virus is combined, so blood plasma can filter viral ability and reach more than 105 when the filter membrane by combined films core 4 with the medium of filter membrane.At last, treated blood plasma is flowed out by the outlet 21 of lower cover 2, and after measured, other protein in the blood plasma are not subjected to any loss.
A kind of enforcement the solution of the present invention is listed below as an example, and this does not also mean that the present invention only limits to adopt this method.
Claims (10)
1. one kind is carried out filtering method to human plasma virus, comprise that cell separation separates two parts with virus, it is characterized in that it is to adopt membrane filtration and the combined method of compatible filtering that virus is separated, on the one hand by the film mechanical filter, virus is separated from blood plasma less than the various membrane materials of virus with the aperture, pass through compatible filtering on the other hand, there is the film of affinity combined with various to virus, when blood plasma makes up filter membrane by this, virus and blood fat will be adsorbed, and the various graininess harmful substances of elimination.
2. one kind is carried out filtering method to human plasma virus, comprises that cell separation separates two parts with virus, it is characterized in that it is that the method for employing membrane filtration is removed virus that virus is separated.
3. one kind is carried out filtering method to human plasma virus, comprises that cell separation separates two parts with virus, it is characterized in that it is that the method for employing affinity filtration is removed virus that virus is separated.
4. one kind is carried out filtering device to human plasma virus, at least comprise the combined films that housing and several layers filter membrane constitute, housing comprises loam cake and lower cover, on be covered with plasma inlet and air vent, under be covered with blood plasma outlet, it is characterized in that described combined films is combined by DELP-90SP-DELP-DELP-0.2 μ film five tunics to form.
5. plasma filtering device according to claim 1 is characterized in that: the upper surface of lower cover is provided with many spaced projectioies, and combined films is fixed between loam cake and the lower cover, and is resisted against on the projection of lower cover.
6. plasma filtering device according to claim 1 and 2, the projection that covers under it is characterized in that is the center of circle with the center of lower cover, evenly distributed circular arc.
7. plasma filtering device according to claim 1 is characterized in that upper and lower covers is glued together with glue.
8. plasma filtering device according to claim 3 is characterized in that loam cake is provided with corresponding annular protrusion in the junction, and corresponding these projectioies of lower cover are provided with annular groove, and the projection of loam cake is accommodated in the groove of lower cover.
9. plasma filtering device according to claim 1 is characterized in that an inner ring accommodates in the lower cover, lower cover with the inboard breach that forms in loam cake junction, the inner ring lateral margin extends outwardly in this breach.
10. plasma filtering device according to claim 1 is characterized in that plasma inlet is arranged on the general center of loam cake, and air vent is near plasma inlet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031159257A CN1531978A (en) | 2003-03-21 | 2003-03-21 | Method and device for filtering human plasma virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031159257A CN1531978A (en) | 2003-03-21 | 2003-03-21 | Method and device for filtering human plasma virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1531978A true CN1531978A (en) | 2004-09-29 |
Family
ID=34284501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031159257A Pending CN1531978A (en) | 2003-03-21 | 2003-03-21 | Method and device for filtering human plasma virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1531978A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102553355A (en) * | 2011-09-06 | 2012-07-11 | 北京双鹤药业股份有限公司 | Application of clay material, ceramic material and glass material in preparation of pulmonary surfactant extract of calf, pig or other mammals |
| US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
| CN111821735A (en) * | 2020-06-20 | 2020-10-27 | 徐州市中心医院 | Fully-closed autologous bone marrow mononuclear cell and platelet rapid circulating filtration concentrator for regenerative medicine |
-
2003
- 2003-03-21 CN CNA031159257A patent/CN1531978A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
| CN102553355A (en) * | 2011-09-06 | 2012-07-11 | 北京双鹤药业股份有限公司 | Application of clay material, ceramic material and glass material in preparation of pulmonary surfactant extract of calf, pig or other mammals |
| CN102553355B (en) * | 2011-09-06 | 2014-11-19 | 华润双鹤药业股份有限公司 | Application of clay material, ceramic material and glass material in preparation of pulmonary surfactant extract of calf, pig or other mammals |
| CN111821735A (en) * | 2020-06-20 | 2020-10-27 | 徐州市中心医院 | Fully-closed autologous bone marrow mononuclear cell and platelet rapid circulating filtration concentrator for regenerative medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1121217C (en) | Photopheresis treatment of leukocytes | |
| RU2072889C1 (en) | Filter for filtering spinal fluid | |
| US6168718B1 (en) | Method for purifying blood plasma and apparatus suitable therefor | |
| WO1997036581A9 (en) | Photopheresis treatment of leukocytes | |
| WO1992000132A1 (en) | Process and apparatus for removal of dna and viruses | |
| US6228995B1 (en) | Method for removal of psoralens from biological fluids | |
| JPH0134627B2 (en) | ||
| DE69734450T2 (en) | PHOTOPHERESIS TREATMENT OF HCV INFECTIONS | |
| CN1531978A (en) | Method and device for filtering human plasma virus | |
| WO1998019722A1 (en) | Method for purifying blood plasma and apparatus suitable therefor | |
| FI105453B (en) | A method of producing a vaccine against HIV retroviral infection | |
| CN100581600C (en) | Extracorporeal blood dialysis filtering method and apparatus for treating cerebral apoplexy | |
| CN1249952A (en) | Blood plasma virus deactivating method and apparatus | |
| CN2643903Y (en) | Multifunctional external filtering apparatus of plasma | |
| US11197924B2 (en) | Photochemical preparation method for autologous plasma inactivated vaccine for treating AIDS | |
| CN2643902Y (en) | External filtering device capable of reducing jaundice and GPT in plasm | |
| CN2751810Y (en) | External blood plasma dialysis filtering box for treating cerebral apoplexy | |
| CN1531977A (en) | Multipurpose extrasomatic plasma filtering method and device | |
| CN205885876U (en) | Hyperlipidemia treatment filter | |
| CN2643904Y (en) | Myocarditic virus filtration and removal device through extracorporeal circulation | |
| Siami et al. | The current status of therapeutic apheresis devices in the United States | |
| CN211584545U (en) | Blood purification device with membrane separation and perfusion coupling | |
| CN1208091C (en) | Virus deactivating method with immobilized solvent or immobilized solvent-detergent | |
| JP3330420B2 (en) | Bradykinin adsorbent | |
| CN2643901Y (en) | Hepatitis B virus filtrating and eliminating apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jianfu Biological Technology Co., Ltd., Shanghai Document name: Notification before expiration of term |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Jianfu Biological Technology Co., Ltd., Shanghai Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |